Variability of ferritin measurements in chronic kidney disease; implications for iron management

被引:47
|
作者
Ford, Bradley A. [1 ]
Coyne, Daniel W. [2 ]
Eby, Charles S. [1 ,2 ]
Scott, Mitchell G. [1 ]
机构
[1] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA
[2] Washington Univ, Dept Med, St Louis, MO 63110 USA
关键词
ferritin; iron; hemodialysis; anemia; ANEMIC HEMODIALYSIS-PATIENTS; HIGH SERUM FERRITIN; INTRAVENOUS IRON; TRANSFERRIN SATURATION; DIALYSIS PATIENTS; IV IRON; DEFICIENCY; GLUCONATE; TRIAL; REDUCTION;
D O I
10.1038/ki.2008.526
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Serum ferritin levels are a proxy measure of iron stores; existing guidelines for managing anemia in hemodialysis patients suggest that serum ferritin concentrations should be maintained at > 200 ng/ml. The KDOQI recommendations further state there is insufficient evidence advocating routine intravenous iron when ferritin levels exceed 500 ng/ml. Here we determined the interassay differences and short-term intraindividual variability of serum ferritin measurements in patients on chronic hemodialysis to illustrate how these variances may affect treatment decisions. Intermethod variations of up to 150 ng/ml were found comparing six commonly used ferritin assays that evaluated thirteen pools of serum from hemodialysis and nonhemodialysis patients. The intraindividual variability for ferritin in 60 stable hemodialysis patients ranged between 2-62% measured over an initial two-week period and from 3-52% when factored over a six-week period. Our results suggests that single serum ferritin values should not be used to guide clinical decisions regarding treatment of chronic hemodialysis patients with intravenous iron due to significant analytical and intraindividual variability.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [21] Safety of intravenous iron use in chronic kidney disease
    Kalra, Philip A.
    Bhandari, Sunil
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2016, 25 (06) : 529 - 535
  • [22] Iron deficiency in children with early chronic kidney disease
    Rossana Baracco
    Sermin Saadeh
    Rudolph Valentini
    Gaurav Kapur
    Amrish Jain
    Tej K. Mattoo
    Pediatric Nephrology, 2011, 26 : 2077 - 2080
  • [23] Acute Effects of Iron Sucrose and Iron Carboxymaltose on Endothelial Function in Nondialysis Chronic Kidney Disease Patients
    Mehedinti, Ana Maria
    Lipan, Mariana
    Stancu, Simona
    Mircescu, Gabriel
    Capusa, Cristina
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (02) : E175 - E181
  • [24] Iron, hepcidin and chronic kidney disease
    Fievet, Patrick
    Brazier, Francois
    NEPHROLOGIE & THERAPEUTIQUE, 2011, 7 (02): : 86 - 91
  • [25] Intravenous iron and chronic kidney disease
    Auerbach, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (11) : 1083 - 1083
  • [26] Importance of Ferritin for Optimizing Anemia Therapy in Chronic Kidney Disease
    Nakanishi, Takeshi
    Kuragano, Takahiro
    Nanami, Masayoshi
    Otaki, Yoshinaga
    Nonoguchi, Hiroshi
    Hasuike, Yukiko
    AMERICAN JOURNAL OF NEPHROLOGY, 2010, 32 (05) : 439 - 446
  • [27] Reconsideration of the anemia management strategy for chronic kidney disease and dialysis patients
    Daimon, Shoichiro
    RENAL REPLACEMENT THERAPY, 2025, 11 (01)
  • [28] Hepcidin is a Potential Regulator of Iron Status in Chronic Kidney Disease
    Tsuchiya, Ken
    Nitta, Kosaku
    THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (01) : 1 - 8
  • [29] A randomized trial of intravenous and oral iron in chronic kidney disease
    Agarwal, Rajiv
    Kusek, John W.
    Pappas, Maria K.
    KIDNEY INTERNATIONAL, 2015, 88 (04) : 905 - 914
  • [30] Immunosenescence, gut dysbiosis, and chronic kidney disease: Interplay and implications for clinical management
    Lee, Tao Han
    Chen, Jia-Jin
    Wu, Chao-Yi
    Lin, Ting-Yun
    Hung, Szu-Chun
    Yang, Huang-Yu
    BIOMEDICAL JOURNAL, 2024, 47 (02)